VIRALEZE Nasal Spray to be distributed in Hong Kong and Macau
MELBOURNE, Australia, Oct. 25, 2022 /PRNewswire/ -- An antiviral barrier nasal spray called VIRALEZE™ will launch inHong Kong and Macau in the coming weeks, following a recent sales and distribution agreement between the product's developer Starpharma and Hengan Pharmacare Company Limited, a subs...
Starpharma presents compelling data in Prostate Cancer at ESMO
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a patented, highly water soluble dendrimer nanopartic...
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC,Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibod...
VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure
MELBOURNE, Australia, July 20, 2022 /PRNewswire/ -- Starpharma's broad-spectrum VIRALEZE™ nasal spray has shown protection against infection with the highly transmissible SARS-CoV-2 Omicron variant in a stringent viral challenge model. VIRALEZE™ is a broad-spectrum barrier nasal spray, developed ...
Australian developed VIRALEZE™ nasal spray relaunched by LloydsPharmacy in the UK
MELBOURNE, Australia, June 30, 2022 /PRNewswire/ -- UK consumers will again be able to buy VIRALEZE™, an easy-to-use barrier nasal spray, from LloydsPharmacy, following its relaunch online, with instore availability to follow shortly. Extensive antiviral testing undertaken at the globally renowne...
Active agent in Australian-developed nasal spray >99.5% active against the Omicron SARS-CoV-2 variant
* The antiviral agent in VIRALEZE™ antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 * SPL7013 showed potent antiviral activity and was virucidal against the Omicron varia...
Starpharma signs distribution agreement for VIRALEZE™ antiviral nasal spray in Vietnam
* Starpharma has signed a 5-year supply and distribution agreement for VIRALEZE™ inVietnam * The agreement includes a minimum commitment of 1 million units in the first year * VIRALEZE™ is scheduled to be officially launched in Vietnam today, following its registration for sale this week ...
VIRALEZE™ antiviral nasal spray registered in Vietnam with launch to follow this week
MELBOURNE, Australia, Dec. 1, 2021 /PRNewswire/ -- Australian biotech company
Starpharma
Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100%
of evaluable patients with Stage IV prostate cancer have had efficacy
responses, utilising one or more standard measures of disease.
DEP® cabazitaxel
Starpharma releases positive DEP® phase 2 interim results in prostate cancer
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel. The company showed that 100% of evaluable patients with (Stage IV) metastatic prostat...
VIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in Italy
MELBOURNE, Australia, Oct. 8, 2021 /PRNewswire/ -- Australian biotech company Starpharma today announced it has signed a sales and distribution agreement for its VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company...
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model
MELBOURNE, Australia, Aug. 23, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection[1]. Viraleze adm...
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
* New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE™ nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure * SPL7013, the antiviral agent in V...
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants
MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today
shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9%
effective against three of the four deadliest variants of the SARS-CoV-2 virus.
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants
MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today
shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9%
effective against three of the four deadliest variants of the SARS-CoV-2 virus.
Viraleze registered for sale in Covid-ravaged India
MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population
will have access from today to the Australian developed anti-COVID nasal spray
Viraleze™ following its registration in the country.
